Ignacio I Wistuba

List of Publications by Year in descending order

312 papers	36,436 citations	6124 83 h-index	4622 176 g-index
323 all docs	323 docs citations	323 times ranked	45717 citing authors

#	Article	IF	Citations
1	The immunogenomic landscape of resected intrahepatic cholangiocarcinoma. Hepatology, 2022, 75, 297-308.	3.6	32
2	SRGN-Triggered Aggressive and Immunosuppressive Phenotype in a Subset of TTF-1â€“Negative Lung Adenocarcinomas. Journal of the National Cancer Institute, 2022, 114, 290-301.	3.0	18
3	Artificial intelligence strategy integrating morphologic and architectural biomarkers provides robust diagnostic accuracy for disease progression in chronic lymphocytic leukemia. Journal of Pathology, 2022, 256, 4-14.	2.1	18
4	Effector memory cytotoxic CD3+/CD8+/CD45RO+ T cells are predictive of good survival and a lower risk of recurrence in triple-negative breast cancer. Modern Pathology, 2022, 35, 601-608.	2.9	10
5	Surgical approach does not influence changes in circulating immune cell populations following lung cancer resection. Lung Cancer, 2022, 164, 69-75.	0.9	2
6	Expression of TRPS1 in phyllodes tumor and sarcoma of the breast. Human Pathology, 2022, 121, 73-80.	1.1	18
7	Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes. , 2022, 10, e003082.		11
8	ISA101 and nivolumab for HPV-16⁺ cancer: updated clinical efficacy and immune correlates of response. , 2022, 10, e004232.		38
9	AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1+ CD8 TÂcells. Cell Reports Medicine, 2022, 3, 100554.	3.3	29
10	MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers. Nature Communications, 2022, 13, 1797.	5.8	23
11	Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors. JAMA Oncology, 2022, 8, 904.	3.4	13
12	Dynamic expression of Schlafen 11 (SLFN11) in circulating tumour cells as a liquid biomarker in small cell lung cancer. British Journal of Cancer, 2022, 127, 569-576.	2.9	8
13	Diminished Immune Surveillance during Histologic Progression of Intraductal Papillary Mucinous Neoplasms Offers a Therapeutic Opportunity for Cancer Interception. Clinical Cancer Research, 2022, 28, 1938-1947.	3.2	11
14	Immunogenomic intertumor heterogeneity across primary and metastatic sites in a patient with lung adenocarcinoma. Journal of Experimental and Clinical Cancer Research, 2022, 41, 172.	3.5	2
15	Chronic Lymphocytic Leukemia Progression Diagnosis with Intrinsic Cellular Patterns via Unsupervised Clustering. Cancers, 2022, 14, 2398.	1.7	6
16	Mutational Activation of the NRF2 Pathway Upregulates Kynureninase Resulting in Tumor Immunosuppression and Poor Outcome in Lung Adenocarcinoma. Cancers, 2022, 14, 2543.	1.7	16
17	The microRNA-183/96/182 cluster inhibits lung cancer progression and metastasis by inducing an interleukin-2-mediated antitumor CD8⁺ cytotoxic T-cell response. Genes and Development, 2022, 36, 582-600.	2.7	9
18	Naproxen chemoprevention promotes immune activation in Lynch syndrome colorectal mucosa. Gut, 2021, 70, 555-566.	6.1	37

#	Article	IF	Citations
19	Female Gender Predicts Augmented Immune Infiltration in Lung Adenocarcinoma. Clinical Lung Cancer, 2021, 22, e415-e424.	1.1	10
20	TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer. Modern Pathology, 2021, 34, 710-719.	2.9	90
21	Pathologic Assessment of Lung Squamous Cell Carcinoma After Neoadjuvant Immunotherapy. Journal of Thoracic Oncology, 2021, 16, e9-e10.	0.5	6
22	Altered Regulation of HIF-1Î± in Naive- and Drug-Resistant EGFR-Mutant NSCLC: Implications for a Vascular Endothelial Growth Factor-Dependent Phenotype. Journal of Thoracic Oncology, 2021, 16, 439-451.	0.5	34
23	Expression of BCL2 alternative proteins and association with outcome in CLL patients treated with venetoclax. Leukemia and Lymphoma, 2021, 62, 1129-1135.	0.6	6
24	Neoadjuvant Chemotherapy Increases Cytotoxic T Cell, Tissue Resident Memory T Cell, and B Cell Infiltration in Resectable NSCLC. Journal of Thoracic Oncology, 2021, 16, 127-139.	0.5	48
25	Evolution of DNA methylome from precancerous lesions to invasive lung adenocarcinomas. Nature Communications, 2021, 12, 687.	5.8	30
26	Identification of distinct immune landscapes using an automated nine-color multiplex immunofluorescence staining panel and image analysis in paraffin tumor tissues. Scientific Reports, 2021, 11, 4530.	1.6	27
27	Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nature Medicine, 2021, 27, 504-514.	15.2	357
28	Pathology and Classification of SCLC. Cancers, 2021, 13, 820.	1.7	68
29	PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nature Reviews Clinical Oncology, 2021, 18, 345-362.	12.5	646
30	Elevated NSD3 histone methylation activity drives squamous cell lung cancer. Nature, 2021, 590, 504-508.	13.7	79
31	Rare deleterious germline variants and risk of lung cancer. Npj Precision Oncology, 2021, 5, 12.	2.3	19
32	Single-Cell Expression Landscape of SARS-CoV-2 Receptor ACE2 and Host Proteases in Normal and Malignant Lung Tissues from Pulmonary Adenocarcinoma Patients. Cancers, 2021, 13, 1250.	1.7	7
33	Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell, 2021, 39, 346-360.e7.	7.7	422
34	Cell-autonomous immune gene expression is repressed in pulmonary neuroendocrine cells and small cell lung cancer. Communications Biology, 2021, 4, 314.	2.0	44
35	Global analysis of shared TÂcell specificities in human non-small cell lung cancer enables HLA inference and antigen discovery. Immunity, 2021, 54, 586-602.e8.	6.6	80
36	The Transcriptomic Landscape of Mismatch Repair-Deficient Intestinal Stem Cells. Cancer Research, 2021, 81, 2760-2773.	0.4	7

#	Article	IF	Citations
37	Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases. Clinical Cancer Research, 2021, 27, 3039-3049.	3.2	28
38	CD8+ T cells inhibit metastasis and CXCL4 regulates its function. British Journal of Cancer, 2021, 125, 176-189.	2.9	21
39	Multiplex Immunofluorescence Tyramide Signal Amplification for Immune Cell Profiling of Paraffin-Embedded Tumor Tissues. Frontiers in Molecular Biosciences, 2021, 8, 667067.	1.6	26
40	Contextual cues from cancer cells govern cancer-associated fibroblast heterogeneity. Cell Reports, 2021, 35, 109009.	2.9	18
41	Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target. Journal of Thoracic Oncology, 2021, 16, 583-600.	0.5	62
42	Resolving the Spatial and Cellular Architecture of Lung Adenocarcinoma by Multiregion Single-Cell Sequencing. Cancer Discovery, 2021, 11, 2506-2523.	7.7	68
43	Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features. Nature Communications, 2021, 12, 2722.	5.8	74
44	Implementation of a Novel Web-Based Lesion Selection Tool to Improve Acquisition of Tumor Biopsy Specimens. Journal of Immunotherapy and Precision Oncology, 2021, 4, 45-52.	0.6	5
45	Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma. Cancer Discovery, 2021, 11, 2738-2747.	7.7	37
46	Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial. Clinical and Translational Medicine, 2021, 11, e491.	1.7	26
47	Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer. Clinical Cancer Research, 2021, 27, 5365-5375.	3.2	29
48	A wake-up call for cancer DNA damage: the role of Schlafen 11 (SLFN11) across multiple cancers. British Journal of Cancer, 2021, 125, 1333-1340.	2.9	22
49	Multiplex Tissue Imaging Harmonization: A Multicenter Experience from CIMAC-CIDC Immuno-Oncology Biomarkers Network. Clinical Cancer Research, 2021, 27, 5072-5083.	3.2	10
50	Multi-institutional TSA-amplified Multiplexed Immunofluorescence Reproducibility Evaluation (MITRE) Study. , 2021, 9, e002197.		44
51	Immune Profiling Mass Cytometry Assay Harmonization: Multicenter Experience from CIMAC-CIDC. Clinical Cancer Research, 2021, 27, 5062-5071.	3.2	8
52	Estrogen Promotes Resistance to Bevacizumab in Murine Models of NSCLC. Journal of Thoracic Oncology, 2021, 16, 2051-2064.	0.5	6
53	The Combiome Hypothesis: Selecting Optimal Treatment for Cancer Patients. Clinical Lung Cancer, 2021, , .	1.1	4
54	Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy. Clinical Cancer Research, 2021, 27, 5878-5890.	3.2	30

#	Article	IF	Citations
55	Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer. Nature Communications, 2021, 12, 5045.	5.8	42
56	Overexpression of CD73 in pancreatic ductal adenocarcinoma is associated with immunosuppressive tumor microenvironment and poor survival. Pancreatology, 2021, 21, 942-949.	0.5	16
57	Evaluation of Pathologic Response in Lymph Nodes of Patients With Lung Cancer Receiving Neoadjuvant Chemotherapy. Journal of Thoracic Oncology, 2021, 16, 1289-1297.	0.5	27
58	BCL-W expression associates with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified. Blood Cancer Journal, 2021, 11, 153.	2.8	1
59	Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. Journal of Thoracic Oncology, 2021, 16, 1647-1662.	0.5	274
60	Network for Biomarker Immunoprofiling for Cancer Immunotherapy: Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC). Clinical Cancer Research, 2021, 27, 5038-5048.	3.2	13
61	CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma. Cancer Immunology, Immunotherapy, 2021, 70, 1965-1976.	2.0	14
62	Transition From a Standard to a Hybrid On-Site and Remote Anatomic Pathology Training Model During the Coronavirus Disease 2019 (COVID-19) Pandemic. Archives of Pathology and Laboratory Medicine, 2021, 145, 22-31.	1.2	25
63	An analysis of research biopsy core variability from over 5000 prospectively collected core samples. Npj Precision Oncology, 2021, 5, 94.	2.3	4
64	NSD2 dimethylation at H3K36 promotes lung adenocarcinoma pathogenesis. Molecular Cell, 2021, 81, 4481-4492.e9.	4.5	42
65	SirpÎ± and CSF1R Positive Tissue Macrophages Are Increased in Patients with Follicular Lymphoma Who Relapse after Frontline Lenalidomide and Rituximab. Blood, 2021, 138, 1336-1336.	0.6	0
66	Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer. Nature Communications, 2021, 12, 6655.	5.8	24
67	The histologic phenotype of lung cancers is associated with transcriptomic features rather than genomic characteristics. Nature Communications, 2021, 12, 7081.	5.8	16
68	The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma. Clinical Cancer Research, 2020, 26, 892-901.	3.2	80
69	Lymphovascular Invasion Is Associated With Mutational Burden and PD-L1 in Resected Lung Cancer. Annals of Thoracic Surgery, 2020, 109, 358-366.	0.7	9
70	Therapeutic targeting of the PI4K2A/PKR lysosome network is critical for misfolded protein clearance and survival in cancer cells. Oncogene, 2020, 39, 801-813.	2.6	16
71	A proposal for pathologic processing of breast implant capsules in patients with suspected breast implant anaplastic large cell lymphoma. Modern Pathology, 2020, 33, 367-379.	2.9	29
72	RUVBL1/RUVBL2 ATPase Activity Drives PAQosome Maturation, DNA Replication and Radioresistance in Lung Cancer. Cell Chemical Biology, 2020, 27, 105-121.e14.	2.5	38

#	Article	IF	Citations
73	Multifactorial Deep Learning Reveals Pan-Cancer Genomic Tumor Clusters with Distinct Immunogenomic Landscape and Response to Immunotherapy. Clinical Cancer Research, 2020, 26, 2908-2920.	3.2	30
74	From clinical specimens to human cancer preclinical modelsâ€"a journey the NCIâ€cell line databaseâ€"25 years later. Journal of Cellular Biochemistry, 2020, 121, 3986-3999.	1.2	6
75	Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation. Oncogene, 2020, 39, 1846-1859.	2.6	29
76	Round Robin Evaluation of MET Protein Expression in Lung Adenocarcinomas Improves Interobserver Concordance. Applied Immunohistochemistry and Molecular Morphology, 2020, 28, 669-677.	0.6	5
77	Molecular differences across invasive lung adenocarcinoma morphological subgroups. Translational Lung Cancer Research, 2020, 9, 1029-1040.	1.3	3
78	Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncology, The, 2020, 21, 1413-1422.	5.1	475
79	Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion. Nature Communications, 2020, 11, 4520.	5.8	218
80	Evolution of Genomic and T-cell Repertoire Heterogeneity of Malignant Pleural Mesothelioma Under Dasatinib Treatment. Clinical Cancer Research, 2020, 26, 5477-5486.	3.2	15
81	Sarcomatoid Mesothelioma: A CDKN2A molecular analysis of 53 cases with immunohistochemical correlation with BAP1. Pathology Research and Practice, 2020, 216, 153267.	1.0	7
82	Multiomics profiling of primary lung cancers and distant metastases reveals immunosuppression as a common characteristic of tumor cells with metastatic plasticity. Genome Biology, 2020, 21, 271.	3.8	36
83	The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation. , 2020, 8, e000155.		140
84	Neutrophil expansion defines an immunoinhibitory peripheral and intratumoral inflammatory milieu in resected non-small cell lung cancer: a descriptive analysis of a prospectively immunoprofiled cohort. , 2020, 8, e000405.		33
85	Hypertrophic lichenoid dermatitis immuneâ€related adverse event during combined immune checkpoint and exportin inhibitor therapy: A diagnostic pitfall for superficially invasive squamous cell carcinoma. Journal of Cutaneous Pathology, 2020, 47, 954-959.	0.7	8
86	Plasma-Derived Extracellular Vesicles Convey Protein Signatures That Reflect Pathophysiology in Lung and Pancreatic Adenocarcinomas. Cancers, 2020, 12, 1147.	1.7	20
87	Clinical and Genomic Characteristics of Small Cell Lung Cancer in Never Smokers. Chest, 2020, 158, 1723-1733.	0.4	16
88	An in vivo functional genomics screen of nuclear receptors and their co-regulators identifies FOXA1 as an essential gene in lung tumorigenesis. Neoplasia, 2020, 22, 294-310.	2.3	21
89	Decrease in tumor content assessed in biopsies is associated with improved treatment outcome response to pembrolizumab in patients with rare tumors. , 2020, 8, e000665.		8
90	Interplay between estrogen and Stat3/NF-ÎºB-driven immunomodulation in lung cancer. Carcinogenesis, 2020, 41, 1529-1542.	1.3	9

#	Article	IF	Citations
91	A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma. Oncologist, 2020, 25, e1457-e1463.	1.9	7
92	A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee. Journal of Thoracic Oncology, 2020, 15, 1599-1610.	0.5	234
93	Genomic assessment distinguishes intrapulmonary metastases from synchronous primary lung cancers. Journal of Thoracic Disease, 2020, 12, 1952-1959.	0.6	6
94	IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy. Journal of Thoracic Oncology, 2020, 15, 709-740.	0.5	205
95	STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype. Journal of Thoracic Oncology, 2020, 15, 777-791.	0.5	94
96	Computational Staining of Pathology Images to Study the Tumor Microenvironment in Lung Cancer. Cancer Research, 2020, 80, 2056-2066.	0.4	88
97	PI4KIIIÎ² is a therapeutic target in chromosome 1qâ€“amplified lung adenocarcinoma. Science Translational Medicine, 2020, 12, .	5.8	41
98	Procedural Requirements and Recommendations for Multiplex Immunofluorescence Tyramide Signal Amplification Assays to Support Translational Oncology Studies. Cancers, 2020, 12, 255.	1.7	58
99	A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2020, 26, 3525-3536.	3.2	22
100	Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma. Cancer Cell, 2020, 37, 720-734.e13.	7.7	74
101	eIF5B drives integrated stress response-dependent translation of PD-L1 in lung cancer. Nature Cancer, 2020, 1, 533-545.	5.7	73
102	Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemotherapy. Clinical Lung Cancer, 2020, 21, 341-348.	1.1	70
103	18F-fluorodeoxyglucose positron emission tomography correlates with tumor immunometabolic phenotypes in resected lung cancer. Cancer Immunology, Immunotherapy, 2020, 69, 1519-1534.	2.0	21
104	T-Cell Repertoire in Combination with T-Cell Density Predicts Clinical Outcomes in Patients with Merkel Cell Carcinoma. Journal of Investigative Dermatology, 2020, 140, 2146-2156.e4.	0.3	14
105	Multiplex Immunofluorescence Assays. Methods in Molecular Biology, 2020, 2055, 467-495.	0.4	44
106	LKB1/STK11 Expression in Lung Adenocarcinoma and Associations With Patterns of Recurrence. Annals of Thoracic Surgery, 2020, 110, 1131-1138.	0.7	8
107	Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. Journal of Thoracic Oncology, 2020, 15, 1449-1459.	0.5	109
108	The International Association for the Study of Lung Cancer Global Survey on Molecular Testing in Lung Cancer. Journal of Thoracic Oncology, 2020, 15, 1434-1448.	0.5	107

#	Article	IF	Citations
109	Comprehensive T cell repertoire characterization of non-small cell lung cancer. Nature Communications, 2020, 11, 603.	5.8	140
110	Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer. Nature Cancer, 2020, 1, 423-436.	5.7	218
111	Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy. Cancer Cell, 2019, 36, 168-178.e4.	7.7	240
112	Tumor cellular proliferation is associated with enhanced immune checkpoint expression in stage I nonâ€“small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2019, 158, 911-919.e6.	0.4	21
113	Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma. Nature Communications, 2019, 10, 2978.	5.8	91
114	Characterization and Comparison of GITR Expression in Solid Tumors. Clinical Cancer Research, 2019, 25, 6501-6510.	3.2	37
115	Tyrosine Threonine Kinase Inhibition Eliminates Lung Cancers by Augmenting Apoptosis and Polyploidy. Molecular Cancer Therapeutics, 2019, 18, 1775-1786.	1.9	21
116	Hybrid oncocytic/chromophobe renal tumors are molecularly distinct from oncocytoma and chromophobe renal cell carcinoma. Modern Pathology, 2019, 32, 1698-1707.	2.9	35
117	Development and Application of Duplex Sequencing Strategy for Cell-Free DNAâ€“Based Longitudinal Monitoring of Stage IV Colorectal Cancer. Journal of Molecular Diagnostics, 2019, 21, 994-1009.	1.2	4
118	Non-invasive genotyping of metastatic colorectal cancer using circulating cell free DNA. Cancer Genetics, 2019, 237, 82-89.	0.2	7
119	Sphingosine Kinase 1 Signaling Promotes Metastasis of Triple-Negative Breast Cancer. Cancer Research, 2019, 79, 4211-4226.	0.4	48
120	PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Nonâ€“Small Cell Lung Cancer. Journal of Thoracic Oncology, 2019, 14, 1021-1031.	0.5	79
121	Genomic landscape of allelic imbalance in premalignant atypical adenomatous hyperplasias of the lung. EBioMedicine, 2019, 42, 296-303.	2.7	15
122	Gene expression profiling of lichenoid dermatitis immuneâ€related adverse event from immune checkpoint inhibitors reveals increased CD14⁺ and CD16⁺ monocytes driving an innate immune response. Journal of Cutaneous Pathology, 2019, 46, 627-636.	0.7	27
123	ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism. Science Translational Medicine, 2019, 11, .	5.8	42
124	An Integrated Next-Generation Sequencing System for Analyzing DNA Mutations, Gene Fusions, and RNA Expression in Lung Cancer. Translational Oncology, 2019, 12, 836-845.	1.7	19
125	Rational â€œErrorâ€•Approach to Evaluating Molecular Barcoded Next-Generation Sequencing Data Identifies Low-Frequency Mutations in Hematologic Malignancies. Journal of Molecular Diagnostics, 2019, 21, 471-482.	1.2	1
126	Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer. Journal of Thoracic Oncology, 2019, 14, 377-407.	0.5	212

#	Article	IF	Citations
127	B7-H3 Expression in Merkel Cell Carcinomaâ€“Associated Endothelial Cells Correlates with Locally Aggressive Primary Tumor Features and Increased Vascular Density. Clinical Cancer Research, 2019, 25, 3455-3467.	3.2	24
128	Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer. Cancer Discovery, 2019, 9, 646-661.	7.7	555
129	High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancer. , 2019, 7, 351.		39
130	ConvPath: A software tool for lung adenocarcinoma digital pathological image analysis aided by a convolutional neural network. EBioMedicine, 2019, 50, 103-110.	2.7	66
131	Immunotherapy response evaluation with magnetic resonance elastography (MRE) in advanced HCC. , 2019, 7, 329.		33
132	TMPRSS4: A Novel Tumor Prognostic Indicator for the Stratification of Stage IA Tumors and a Liquid Biopsy Biomarker for NSCLC Patients. Journal of Clinical Medicine, 2019, 8, 2134.	1.0	17
133	Inhibitor of Differentiation-1 Sustains Mutant KRAS-Driven Progression, Maintenance, and Metastasis of Lung Adenocarcinoma via Regulation of a FOSL1 Network. Cancer Research, 2019, 79, 625-638.	0.4	19
134	LCE: an open web portal to explore gene expression and clinical associations in lung cancer. Oncogene, 2019, 38, 2551-2564.	2.6	78
135	5 protein-based signature for resectable lung squamous cell carcinoma improves the prognostic performance of the TNM staging. Thorax, 2019, 74, 371-379.	2.7	9
136	Genetic characterization of medullary thyroid cancer in childhood survivors of the Chernobyl accident. Surgery, 2019, 165, 58-63.	1.0	5
137	Centrifuged supernatants from FNA provide a liquid biopsy option for clinical nextâ€generation sequencing of thyroid nodules. Cancer Cytopathology, 2019, 127, 146-160.	1.4	37
138	Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16â€“Related Cancer. JAMA Oncology, 2019, 5, 67.	3.4	344
139	Validation of the 12-gene Predictive Signature for Adjuvant Chemotherapy Response in Lung Cancer. Clinical Cancer Research, 2019, 25, 150-157.	3.2	13
140	Primary Mediastinal Yolk Sac Tumors: An Immunohistochemical Analysis of 14 Cases. Applied Immunohistochemistry and Molecular Morphology, 2019, 27, 125-133.	0.6	12
141	RCRnorm: An integrated system of random-coefficient hierarchical regression models for normalizing NanoString nCounter data. Annals of Applied Statistics, 2019, 13, 1617-1647.	0.5	6
142	Salvaging the supernatant: next generation cytopathology for solid tumor mutation profiling. Modern Pathology, 2018, 31, 1036-1045.	2.9	60
143	Osteoblast-Secreted Factors Mediate Dormancy of Metastatic Prostate Cancer in the Bone via Activation of the TGFÎ²RIIIâ€“p38MAPKâ€“pS249/T252RB Pathway. Cancer Research, 2018, 78, 2911-2924.	0.4	117
144	Major pathologic response and RAD51 predict survival in lung cancer patients receiving neoadjuvant chemotherapy. Cancer Medicine, 2018, 7, 2405-2414.	1.3	22

#	Article	IF	Citations
145	Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer. Cell, 2018, 173, 864-878.e29.	13.5	102
146	Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy. Cell Metabolism, 2018, 27, 977-987.e4.	7.2	398
147	Spatial interaction of tumor cells and regulatory T cells correlates with survival in non-small cell lung cancer. Lung Cancer, 2018, 117, 73-79.	0.9	135
148	Multiregion gene expression profiling reveals heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancer. Modern Pathology, 2018, 31, 947-955.	2.9	56
149	Polo-like kinase 4 inhibition produces polyploidy and apoptotic death of lung cancers. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 1913-1918.	3.3	64
150	Development of an Immune-Pathology Informed Radiomics Model for Non-Small Cell Lung Cancer. Scientific Reports, 2018, 8, 1922.	1.6	108
151	Genome-Wide Gene Expression Changes in the Normal-Appearing Airway during the Evolution of Smoking-Associated Lung Adenocarcinoma. Cancer Prevention Research, 2018, 11, 237-248.	0.7	23
152	Development and Validation of a Predictive Radiomics Model for Clinical Outcomes in Stage I Non-small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1090-1097.	0.4	56
153	Biomarker-Integrated Neoadjuvant Dasatinib Trial in Resectable Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2018, 13, 246-257.	0.5	14
154	Immunohistochemical and Image Analysis-Based Study Shows That Several Immune Checkpoints are Co-expressed in Nonâ€“Small Cell Lung Carcinoma Tumors. Journal of Thoracic Oncology, 2018, 13, 779-791.	0.5	53
155	RAD50 Expression Is Associated with Poor Clinical Outcomes after Radiotherapy for Resected Nonâ€“small Cell Lung Cancer. Clinical Cancer Research, 2018, 24, 341-350.	3.2	31
156	Novel enriched pathways in superficial malignant peripheral nerve sheath tumours and spindle/desmoplastic melanomas. Journal of Pathology, 2018, 244, 97-106.	2.1	17
157	Serum MicroRNAâ€150 Predicts Prognosis for Earlyâ€Stage Nonâ€Small Cell Lung Cancer and Promotes Tumor Cell Proliferation by Targeting Tumor Suppressor Gene SRCIN1. Clinical Pharmacology and Therapeutics, 2018, 103, 1061-1073.	2.3	31
158	Induction Cisplatin Docetaxel Followed by Surgery and Erlotinib in Non-Small Cell Lung Cancer. Annals of Thoracic Surgery, 2018, 105, 418-424.	0.7	26
159	Reduced <scp>IL</scp>â€6 levels and tumorâ€associated phosphoâ€<scp>STAT</scp>3 are associated with reduced tumor development in a mouse model of lung cancer chemoprevention with myoâ€inositol. International Journal of Cancer, 2018, 142, 1405-1417.	2.3	33
160	Update on EGFR Mutational Testing and the Potential of Noninvasive Liquid Biopsy in Nonâ€“Small-cell Lung Cancer. Clinical Lung Cancer, 2018, 19, 105-114.	1.1	22
161	Transcriptome Deconvolution of Heterogeneous Tumor Samples with Immune Infiltration. IScience, 2018, 9, 451-460.	1.9	69
162	Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. Journal of Thoracic Oncology, 2018, 13, 1818-1831.	0.5	133

#	Article	IF	Citations
163	Sex specific function of epithelial STAT3 signaling in pathogenesis of K-ras mutant lung cancer. Nature Communications, 2018, 9, 4589.	5.8	57
164	LMO1 functions as an oncogene by regulating TTK expression and correlates with neuroendocrine differentiation of lung cancer. Oncotarget, 2018, 9, 29601-29618.	0.8	19
165	PI3â€kinase pathway biomarkers in oral cancer and tumor immune cells. Head and Neck, 2018, 41, 615-622.	0.9	4
166	Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (antiâ€“PD-L1). Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E10119-E10126.	3.3	180
167	Reply to Oegema et al.: CFI-400945 and Polo-like kinase 4 inhibition. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E10810-E10811.	3.3	5
168	HORMAD1 Is a Negative Prognostic Indicator in Lung Adenocarcinoma and Specifies Resistance to Oxidative and Genotoxic Stress. Cancer Research, 2018, 78, 6196-6208.	0.4	50
169	Detection of somatic mutations in cell-free DNA in plasma and correlation with overall survival in patients with solid tumors. Oncotarget, 2018, 9, 10259-10271.	0.8	29
170	The oncogenic RNA-binding protein SRSF1 regulates LIG1 in non-small cell lung cancer. Laboratory Investigation, 2018, 98, 1562-1574.	1.7	30
171	STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. Cancer Discovery, 2018, 8, 822-835.	7.7	1,108
172	Liquid Biopsy for Advanced Non-Small Cell LungÂCancer (NSCLC): A Statement Paper from theÂIASLC. Journal of Thoracic Oncology, 2018, 13, 1248-1268.	0.5	515
173	Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer. Nature Communications, 2018, 9, 3114.	5.8	122
174	A Functional Spatial Analysis Platform for Discovery of Immunological Interactions Predictive of Low-Grade to High-Grade Transition of Pancreatic Intraductal Papillary Mucinous Neoplasms. Cancer Informatics, 2018, 17, 117693511878288.	0.9	29
175	Effect of neoadjuvant chemotherapy on the immune microenvironment in nonâ€“small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches. , 2018, 6, 48.		126
176	CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade. Cancer Discovery, 2018, 8, 1156-1175.	7.7	323
177	PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project. Journal of Thoracic Oncology, 2018, 13, 1302-1311.	0.5	589
178	A functional genomic screen in vivo identifies CEACAM5 as a clinically relevant driver of breast cancer metastasis. Npj Breast Cancer, 2018, 4, 9.	2.3	32
179	A novel proteinâ€based prognostic signature improves risk stratification to guide clinical management in earlyâ€stage lung adenocarcinoma patients. Journal of Pathology, 2018, 245, 421-432.	2.1	29
180	Rare Variants in Known Susceptibility Loci and Their Contribution to Risk of Lung Cancer. Journal of Thoracic Oncology, 2018, 13, 1483-1495.	0.5	22

#	Article	IF	Citations
181	Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer. Nature Medicine, 2018, 24, 1047-1057.	15.2	175
182	Requirement for MUC5AC in KRAS-dependent lung carcinogenesis. JCI Insight, 2018, 3, .	2.3	25
183	Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancer. Oncotarget, 2018, 9, 14268-14284.	0.8	12
184	Dynamic changes during the treatment of pancreatic cancer. Oncotarget, 2018, 9, 14764-14790.	0.8	21
185	Concomitant targeting of the mTOR/MAPK pathways: novel therapeutic strategy in subsets of RICTOR/KRAS-altered non-small cell lung cancer. Oncotarget, 2018, 9, 33995-34008.	0.8	9
186	A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Nonâ€“Small Cell Lung Cancer. JAMA Oncology, 2017, 3, 1051.	3.4	658
187	Expression of PD-1 and PD-L1 in thymic epithelial neoplasms. Modern Pathology, 2017, 30, 826-833.	2.9	101
188	Deubiquitinase USP18 Loss Mislocalizes and Destabilizes KRAS in Lung Cancer. Molecular Cancer Research, 2017, 15, 905-914.	1.5	28
189	Lung Cancer Biomarkers. Hematology/Oncology Clinics of North America, 2017, 31, 13-29.	0.9	180
190	Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers. Clinical Cancer Research, 2017, 23, 2891-2904.	3.2	122
191	Study of Preanalytic and Analytic Variables for Clinical Next-Generation Sequencing of Circulating Cell-Free Nucleic Acid. Journal of Molecular Diagnostics, 2017, 19, 514-524.	1.2	22
192	Taxane-Platin-Resistant Lung Cancers Co-develop Hypersensitivity to JumonjiC Demethylase Inhibitors. Cell Reports, 2017, 19, 1669-1684.	2.9	82
193	CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells. Nature, 2017, 546, 168-172.	13.7	222
194	The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2017, 23, 5489-5501.	3.2	55
195	VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nature Medicine, 2017, 23, 551-555.	15.2	467
196	Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. Npj Genomic Medicine, 2017, 2, .	1.7	120
197	Genomic Landscape of Atypical Adenomatous Hyperplasia Reveals Divergent Modes to Lung Adenocarcinoma. Cancer Research, 2017, 77, 6119-6130.	0.4	92
198	Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues. Scientific Reports, 2017, 7, 13380.	1.6	208

#	Article	IF	Citations
199	Programmed cell death ligand 1 and tumorâ€infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation. Cancer, 2017, 123, 4823-4831.	2.0	79
200	Mig-6 deficiency cooperates with oncogenic Kras to promote mouse lung tumorigenesis. Lung Cancer, 2017, 112, 47-56.	0.9	14
201	TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. Cancer Discovery, 2017, 7, 1088-1097.	7.7	160
202	JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Nonâ€“Small Cell Lung Cancer. Molecular Cancer Therapeutics, 2017, 16, 2234-2245.	1.9	72
203	Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional Landscape. Clinical Cancer Research, 2017, 23, 6686-6696.	3.2	66
204	Thy-1+ Cancer-associated Fibroblasts Adversely Impact Lung Cancer Prognosis. Scientific Reports, 2017, 7, 6478.	1.6	34
205	Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with Î²-blockers. Science Translational Medicine, 2017, 9, .	5.8	96
206	Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG S0905). Journal of Thoracic Oncology, 2017, 12, 1299-1308.	0.5	24
207	Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer. Journal of the National Cancer Institute, 2017, 109, .	3.0	41
208	GLI1 Blockade Potentiates the Antitumor Activity of PI3K Antagonists in Lung Squamous Cell Carcinoma. Cancer Research, 2017, 77, 4448-4459.	0.4	24
209	Evidence against a role for jaagsiekte sheep retrovirus in human lung cancer. Retrovirology, 2017, 14, 3.	0.9	9
210	Development of Kras mutant lung adenocarcinoma in mice with knockout of the airway lineageâ€specific gene <scp>G</scp>prc5a. International Journal of Cancer, 2017, 141, 1589-1599.	2.3	33
211	Comprehensive Computational Pathological Image Analysis Predicts Lung Cancer Prognosis. Journal of Thoracic Oncology, 2017, 12, 501-509.	0.5	138
212	PROTOCADHERIN 7 Acts through SET and PP2A to Potentiate MAPK Signaling by EGFR and KRAS during Lung Tumorigenesis. Cancer Research, 2017, 77, 187-197.	0.4	55
213	Spindle cell and pleomorphic (â€œsarcomatoidâ€) carcinomas of the lung: an immunohistochemical analysis of 86 cases. Human Pathology, 2017, 59, 1-9.	1.1	32
214	Challenges in Facing the Lung Cancer Epidemic and Treating Advanced Disease in Latin America. Clinical Lung Cancer, 2017, 18, e71-e79.	1.1	23
215	Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer. Oncotarget, 2017, 8, 28575-28587.	0.8	157
216	Programmed Death Cell Ligand 1 (PD-L1) Is Associated With Survival in Stage I Nonâ€“Small Cell Lung Cancer. Seminars in Thoracic and Cardiovascular Surgery, 2017, 29, 408-415.	0.4	23

#	Article	IF	Citations
217	Versatile ion S5XL sequencer for targeted next generation sequencing of solid tumors in a clinical laboratory. PLoS ONE, 2017, 12, e0181968.	1.1	24
218	The ISG15-specific protease USP18 regulates stability of PTEN. Oncotarget, 2017, 8, 3-14.	0.8	52
219	DNA methylation intratumor heterogeneity in localized lung adenocarcinomas. Oncotarget, 2017, 8, 21994-22002.	0.8	39
220	Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies. Oncotarget, 2017, 8, 73419-73432.	0.8	74
221	Plasma-derived extracellular vesicle proteins as a source of biomarkers for lung adenocarcinoma. Oncotarget, 2017, 8, 95466-95480.	0.8	60
222	Imaging-genetic data mapping for clinical outcome prediction via supervised conditional Gaussian graphical model. , 2016, , .		9
223	The tobacco-specific carcinogen-operated calcium channel promotes lung tumorigenesis via IGF2 exocytosis in lung epithelial cells. Nature Communications, 2016, 7, 12961.	5.8	31
224	Germline Mutation of T790M and Dual/Multiple EGFR Mutations in Patients With Lung Adenocarcinoma. Clinical Lung Cancer, 2016, 17, e5-e11.	1.1	39
225	Genomic Landscape Established by Allelic Imbalance in the Cancerization Field of a Normal Appearing Airway. Cancer Research, 2016, 76, 3676-3683.	0.4	35
226	The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutationâ€“Positive Nonâ€“Small Cell Lung Cancer: Status in 2016. Journal of Thoracic Oncology, 2016, 11, 946-963.	0.5	173
227	Optimizing the <scp>DNA</scp> yield for molecular analysis from cytologic preparations. Cancer Cytopathology, 2016, 124, 254-260.	1.4	49
228	IL6 Blockade Reprograms the Lung Tumor Microenvironment to Limit the Development and Progression of K-rasâ€“Mutant Lung Cancer. Cancer Research, 2016, 76, 3189-3199.	0.4	165
229	Density, Distribution, and Composition of Immune Infiltrates Correlate with Survival in Merkel Cell Carcinoma. Clinical Cancer Research, 2016, 22, 5553-5563.	3.2	96
230	Early Events in the Molecular Pathogenesis of Lung Cancer. Cancer Prevention Research, 2016, 9, 518-527.	0.7	82
231	PIAS1-FAK Interaction Promotes the Survival and Progression of Non-Small Cell Lung Cancer. Neoplasia, 2016, 18, 282-293.	2.3	24
232	XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer. Nature, 2016, 538, 114-117.	13.7	162
233	Fatty Acid Oxidation Mediated by Acyl-CoA Synthetase Long Chain 3 Is Required for Mutant KRAS Lung Tumorigenesis. Cell Reports, 2016, 16, 1614-1628.	2.9	205
234	Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in nonâ€“small cell lung cancer. Lung Cancer, 2016, 99, 79-87.	0.9	108

#	Article	IF	Citations
235	Diagnosis and Molecular Classification of Lung Cancer. Cancer Treatment and Research, 2016, 170, 25-46.	0.2	172
236	Genomic heterogeneity of multiple synchronous lung cancer. Nature Communications, 2016, 7, 13200.	5.8	132
237	Interleukin-11 Receptor Is a Candidate Target for Ligand-Directed Therapy in Lung Cancer. American Journal of Pathology, 2016, 186, 2162-2170.	1.9	18
238	Image Analysisâ€“based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Nonâ€“small Cell Lung Carcinoma Patients. Clinical Cancer Research, 2016, 22, 6278-6289.	3.2	130
239	Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discovery, 2016, 6, 827-837.	7.7	785
240	KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib. Clinical Cancer Research, 2016, 22, 1940-1950.	3.2	15
241	An Expression Signature as an Aid to the Histologic Classification of Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2016, 22, 4880-4889.	3.2	140
242	Cancer-Associated Fibroblasts Induce a Collagen Cross-link Switch in Tumor Stroma. Molecular Cancer Research, 2016, 14, 287-295.	1.5	150
243	STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. Cancer Research, 2016, 76, 999-1008.	0.4	451
244	Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. OncoImmunology, 2016, 5, e1136044.	2.1	55
245	Epithelialâ€“Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma. Clinical Cancer Research, 2016, 22, 3630-3642.	3.2	353
246	Immunoproteasome deficiency is a feature of non-small cell lung cancer with a mesenchymal phenotype and is associated with a poor outcome. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E1555-64.	3.3	174
247	Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations. Cancer Research, 2016, 76, 675-685.	0.4	84
248	Erlotinib and the Risk of Oral Cancer. JAMA Oncology, 2016, 2, 209.	3.4	111
249	A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition. Clinical Cancer Research, 2016, 22, 609-620.	3.2	388
250	ZEB1 drives epithelial-to-mesenchymal transition in lung cancer. Journal of Clinical Investigation, 2016, 126, 3219-3235.	3.9	256
251	Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations. Oncotarget, 2016, 7, 47998-48010.	0.8	21
252	LAPTM4B is associated with poor prognosis in NSCLC and promotes the NRF2-mediated stress response pathway in lung cancer cells. Scientific Reports, 2015, 5, 13846.	1.6	15

#	Article	IF	Citations
253	Expression of insulin-like growth factor I receptor as a biomarker for predicting prognosis in biliary tract cancer patients. Molecular and Clinical Oncology, 2015, 3, 464-470.	0.4	7
254	Ethnicity affects EGFR and KRAS gene alterations of lung adenocarcinoma. Oncology Letters, 2015, 10, 1775-1782.	0.8	27
255	Combined clinical and genomic signatures for the prognosis of early stage non-small cell lung cancer based on gene copy number alterations. BMC Genomics, 2015, 16, 752.	1.2	12
256	Molecular Portraits of Epithelial, Mesenchymal, and Hybrid States in Lung Adenocarcinoma and Their Relevance to Survival. Cancer Research, 2015, 75, 1789-1800.	0.4	179
257	Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 92, 317-324.	0.4	59
258	Regulation of AURKC expression by CpG island methylation in human cancer cells. Tumor Biology, 2015, 36, 8147-8158.	0.8	9
259	Oncogenic mutation profiling in new lung cancer and mesothelioma cell lines. OncoTargets and Therapy, 2015, 8, 195.	1.0	4
260	Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience. Journal of Thoracic Oncology, 2015, 10, 768-777.	0.5	357
261	The 2015 World Health Organization Classification of Lung Tumors. Journal of Thoracic Oncology, 2015, 10, 1243-1260.	0.5	3,313
262	Genetic Mutation of p53 and Suppression of the miR-17â^¼92 Cluster Are Synthetic Lethal in Nonâ€“Small Cell Lung Cancer due to Upregulation of Vitamin D Signaling. Cancer Research, 2015, 75, 666-675.	0.4	39
263	Systematic siRNA Screen Unmasks NSCLC Growth Dependence by Palmitoyltransferase DHHC5. Molecular Cancer Research, 2015, 13, 784-794.	1.5	35
264	An update on clinicopathological, immunohistochemical, and molecular profiles of colloid carcinoma of the lung. Human Pathology, 2015, 46, 836-842.	1.1	20
265	Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities. Cancer Discovery, 2015, 5, 860-877.	7.7	696
266	Long-circulating siRNA nanoparticles for validating Prohibitin1-targeted non-small cell lung cancer treatment. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 7779-7784.	3.3	170
267	Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy. Clinical Epigenetics, 2015, 7, 29.	1.8	13
268	RSPO2 Enhances Canonical Wnt Signaling to Confer Stemness-Associated Traits to Susceptible Pancreatic Cancer Cells. Cancer Research, 2015, 75, 1883-1896.	0.4	65
269	An Integrated Molecular Analysis of Lung Adenocarcinomas Identifies Potential Therapeutic Targets among TTF1-Negative Tumors, Including DNA Repair Proteins and Nrf2. Clinical Cancer Research, 2015, 21, 3480-3491.	3.2	48
270	CDK2 Inhibition Causes Anaphase Catastrophe in Lung Cancer through the Centrosomal Protein CP110. Cancer Research, 2015, 75, 2029-2038.	0.4	40

#	Article	IF	Citations
271	NRF2 regulates serine biosynthesis in nonâ€“small cell lung cancer. Nature Genetics, 2015, 47, 1475-1481.	9.4	579
272	SCT Promoter Methylation Is a Highly Discriminative Biomarker for Lung and Many Other Cancers. IEEE Life Sciences Letters, 2015, 1, 30-33.	1.2	2
273	Primary mediastinal seminomas: a comprehensive immunohistochemical study with a focus on novel markers. Human Pathology, 2015, 46, 376-383.	1.1	33
274	RNA-dependent protein kinase (PKR) depletes nutrients, inducing phosphorylation of AMP-activated kinase in lung cancer. Oncotarget, 2015, 6, 11114-11124.	0.8	7
275	Activation of insulin-like growth factor 1 receptor in patients with non-small cell lung cancer. Oncotarget, 2015, 6, 16746-16756.	0.8	13
276	Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nature Communications, 2014, 5, 5241.	5.8	780
277	Frequent Coamplification and Cooperation between C-MYC and PVT1 Oncogenes Promote Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2014, 9, 998-1007.	0.5	82
278	Prognostic Implications of Tumoral Expression of Insulin Like Growth Factors 1 and 2 in Patients With Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2014, 15, 213-221.	1.1	22
279	Vandetanib and Indwelling Pleural Catheter for Nonâ€“Small-Cell Lung Cancer With Recurrent Malignant Pleural Effusion. Clinical Lung Cancer, 2014, 15, 379-386.	1.1	13
280	Copper transporter CTR1 expression and tissue platinum concentration in non-small cell lung cancer. Lung Cancer, 2014, 85, 88-93.	0.9	63
281	An integrinÂÎ²3â€“KRASâ€“RalB complex drives tumour stemness and resistance to EGFR inhibition. Nature Cell Biology, 2014, 16, 457-468.	4.6	325
282	Thymic neuroendocrine tumors (paraganglioma and carcinoid tumors): a comparative immunohistochemical study of 46 cases. Human Pathology, 2014, 45, 2463-2470.	1.1	34
283	Essential Role of Aldehyde Dehydrogenase 1A3 for the Maintenance of Nonâ€“Small Cell Lung Cancer Stem Cells Is Associated with the STAT3 Pathway. Clinical Cancer Research, 2014, 20, 4154-4166.	3.2	131
284	ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 14788-14793.	3.3	205
285	Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib Â± Onartuzumab in Advanced Nonâ€“Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit. Clinical Cancer Research, 2014, 20, 4488-4498.	3.2	121
286	Aberrant large tumor suppressor 2 (LATS2) gene expression correlates with EGFR mutation and survival in lung adenocarcinomas. Lung Cancer, 2014, 85, 282-292.	0.9	25
287	Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science, 2014, 346, 256-259.	6.0	834
288	A Search for Novel Cancer/Testis Antigens in Lung Cancer Identifies VCX/Y Genes, Expanding the Repertoire of Potential Immunotherapeutic Targets. Cancer Research, 2014, 74, 4694-4705.	0.4	40

#	Article	IF	Citations
289	Phase I Trial of Cisplatin, Pemetrexed, and Imatinib Mesylate in Chemonaive Patients With Unresectable Malignant Pleural Mesothelioma. Clinical Lung Cancer, 2014, 15, 197-201.	1.1	28
290	Current concepts on the molecular pathology of non-small cell lung carcinoma. Seminars in Diagnostic Pathology, 2014, 31, 306-313.	1.0	43
291	Elevated PDGFRB gene copy number gain is prognostic for improved survival outcomes in resected malignant pleural mesothelioma. Annals of Diagnostic Pathology, 2014, 18, 140-145.	0.6	9
292	RHOB influences lung adenocarcinoma metastasis and resistance in a hostâ€sensitive manner. Molecular Oncology, 2014, 8, 196-206.	2.1	27
293	ZEB1 sensitizes lung adenocarcinoma to metastasis suppression by PI3K antagonism. Journal of Clinical Investigation, 2014, 124, 2696-2708.	3.9	101
294	ETS2 Mediated Tumor Suppressive Function and MET Oncogene Inhibition in Human Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2013, 19, 3383-3395.	3.2	146
295	An Epithelialâ€“Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance. Clinical Cancer Research, 2013, 19, 279-290.	3.2	848
296	Validation of a Proliferation-Based Expression Signature as Prognostic Marker in Early Stage Lung Adenocarcinoma. Clinical Cancer Research, 2013, 19, 6261-6271.	3.2	89
297	Human Lung Epithelial Cells Progressed to Malignancy through Specific Oncogenic Manipulations. Molecular Cancer Research, 2013, 11, 638-650.	1.5	192
298	A 12-Gene Set Predicts Survival Benefits from Adjuvant Chemotherapy in Nonâ€“Small Cell Lung Cancer Patients. Clinical Cancer Research, 2013, 19, 1577-1586.	3.2	226
299	g-Protein Coupled Receptor Family C, Group 5, Member A (gprc5a) Expression Is Decreased in the Adjacent Field and Normal Bronchial Epithelia of Patients with Chronic Obstructive Pulmonary Disease and Nonâ€“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 1747-1754.	0.5	51
300	Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer After Neoadjuvant Chemotherapy. Journal of Thoracic Oncology, 2012, 7, 825-832.	0.5	280
301	Molecular Pathogenesis of Non-Small Cell Lung Carcinomas. Journal of Lung Cancer, 2012, 11, 12.	0.2	4
302	Molecular Testing of Nonâ€“Small Cell Lung Carcinoma Biopsy and Cytology Specimens. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 459-464.	1.8	9
303	The BATTLE Trial: Personalizing Therapy for Lung Cancer. Cancer Discovery, 2011, 1, 44-53.	7.7	778
304	Methodological and practical challenges for personalized cancer therapies. Nature Reviews Clinical Oncology, 2011, 8, 135-141.	12.5	159
305	Proteomic Profiling Identifies Pathways Dysregulated in Non-small Cell Lung Cancer and an Inverse Association of AMPK and Adhesion Pathways with Recurrence. Journal of Thoracic Oncology, 2010, 5, 1894-1904.	0.5	57
306	Nrf2 and Keap1 Abnormalities in Nonâ€“Small Cell Lung Carcinoma and Association with Clinicopathologic Features. Clinical Cancer Research, 2010, 16, 3743-3753.	3.2	380

#	Article	IF	Citations
307	Immortalization of human small airway epithelial cells with characteristics of bronchioalveolar stem cells. FASEB Journal, 2009, 23, LB340.	0.2	1
308	Chromosomal Deletions and Progression of Premalignant Lesions: Less Is More. Cancer Prevention Research, 2008, 1, 404-408.	0.7	9
309	LUNG CANCER PRENEOPLASIA. Annual Review of Pathology: Mechanisms of Disease, 2006, 1, 331-348.	9.6	191
310	Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers. Journal of the National Cancer Institute, 2005, 97, 339-346.	3.0	2,194
311	Gallbladder cancer: lessons from a rare tumour. Nature Reviews Cancer, 2004, 4, 695-706.	12.8	394
312	Hypermethylation of the Death-Associated Protein Kinase Promoter Attenuates the Sensitivity to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis in Human Nonâ€“Small Cell Lung Cancer Cells. Molecular Cancer Research, 2004, 2, 685-691.	1.5	28